Abstract 19P
Background
SCLC is highly heterogeneous and can be divided into NE (Neuroendocrine)-high and NE-low groups according to 50 genes on transcriptomic level, harboring different immune microenvironments and potential immunotherapy reactivity. However, this is still far from clinical application since the current three classic NE markers (ChrA, Syn,and CD56) are not very satisfactory either for specificity or sensitivity. It is necessary to explore novel NE markers, that are both close to NE gene subtyping and feasible for clinicopathological use.
Methods
Quantitative detection of NE mRNA genes by Nanostring nCounter as well as INSM1 protein by immunohistochemistry was performed simultaneously on 48 whole slides as testing group. Spearman correlation was applied for consistency analysis of 50 genes and INSM1 protein expression, and the best cut-off for INSM1 expression was validated on 247 tissue microarrays for comparison of the 3 traditional NE protein markers for specificity and sensibility as well as prognostic significance.
Results
In 48 cases, quantitative detection revealed 83.3% for NE-high and 16.7% for NE-low, while for INSM1 protein grouping, it was 79.2% (H-score>100) for NE(INSM1)-high and 20.8% (H-score<=100) for NE(INSM1)-low. NE subtypes defined by INSM1 protein and NE genes had significant consistency in terms of proportion (p=0.026). In addition, NE groups also had consistent clinical characteristics and prognostic trend in the two levels. Patients with NE-high and NE(INSM1)-high tended to be in the advanced stage. Patients with NE-high and NE(INSM1)-high subtypes have a tendency to poor prognosis. In 247 cases of validation exploration, INSM1 expression was positively correlated with 3 classical markers, moreover, in triple-negative cases, INSM1 showed a favorable positive rate (1.5%, 3/198). In addition, NE(INSM1)-high patients showed more bronchial invasion and tumor thrombosis than that of NE(INSM1)-low ones (p<0.05), and the OS rates in the NE(INSM1)-high group were slightly lower than those in the NE(INSM1)-low group.
Conclusions
INSM1 has great potential as a marker of NE differentiation and subgrouping, and also shows a certain correlation with prognosis and some clinicopathological factors.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract